Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × FP-1039 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Endometrial Neoplasms 1 Advanced Cancer 1

Interventions

Nivolumab 15 Surveys and Questionnaires 7 Ipilimumab 7 linrodostat 5 Standard of Care 5 Paclitaxel 5 Bevacizumab 5 temsirolimus 4 Sirolimus 4 Interviews as Topic 4 Gemcitabine 4 Docetaxel 4 relatlimab 3 Vorinostat 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Cetuximab 3 Carboplatin 3 ARRY-334543 3 regorafenib 2 apatinib 2 abemaciclib 2 Trastuzumab 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2 Everolimus 2 Dasatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00687505 2021-12-13

Safety Study of FP-1039 To Treat Cancer

Five Prime Therapeutics, Inc.

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡